Sarepta Therapeutics is a biotechnology company focused on developing first-in-class RNA-based therapeutics which will improve or even save the lives of people affected by serious, life-threatening rare and infectious diseases. The company's pipeline of drugs includes its lead program eteplirsen (for Duchenne muscular dystrophy) as well as potential treatments for some of the world's most lethal infectious diseases.
The company announced today that its lead therapeutic drug for the Marburg Virus, AVI-7288, demonstrated up to 100% survival in a non-human primate study exploring the drug's effect when treatment is delayed to various time points post-infection. The study also showed a significantly higher rate of survival among the primates treated with AVI-7288 when compared to the placebo-treated group when treatment was administered up to 96 hours after infection.
This study was conducted under a US Department of Defense contract and was managed by the Joint Project Manager Transformational Medical Technologies Project Management Office, which is a component of the Joint Program Executive Office for Chemical and Biological Defense. The work is a collaborative effort between Sarepta Therapeutics and scientists at the US Army Medical Research Institute of Infectious Diseases, the Department of Defense's leading medical research laboratory for biological defense.
More specifically, the study showed a high degree of survival (between 83% and 100%) in each of four post-exposure cohorts that received daily treatments with AVI-7288 beginning 1, 24, 48, and 96 hours after infection. This compared to the zero percent survival rate in the placebo-treated control group. Currently at day 27, the study will continue to monitor the surviving primates until the study ends after day 41.
For additional information about Sarepta Therapeutics and its drug pipeline, please visit the company's website at sareptatherapeutics.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net